JP2013507107A5 - - Google Patents

Download PDF

Info

Publication number
JP2013507107A5
JP2013507107A5 JP2012532489A JP2012532489A JP2013507107A5 JP 2013507107 A5 JP2013507107 A5 JP 2013507107A5 JP 2012532489 A JP2012532489 A JP 2012532489A JP 2012532489 A JP2012532489 A JP 2012532489A JP 2013507107 A5 JP2013507107 A5 JP 2013507107A5
Authority
JP
Japan
Prior art keywords
recombinant mva
hiv
mva
expression cassette
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012532489A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013507107A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/006114 external-priority patent/WO2011042180A1/en
Publication of JP2013507107A publication Critical patent/JP2013507107A/ja
Publication of JP2013507107A5 publication Critical patent/JP2013507107A5/ja
Withdrawn legal-status Critical Current

Links

JP2012532489A 2009-10-08 2010-10-06 Hivに対するヒトにおける広範なt細胞応答の生成 Withdrawn JP2013507107A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24964409P 2009-10-08 2009-10-08
US61/249,644 2009-10-08
EP10001264 2010-02-08
EP10001264.0 2010-02-08
PCT/EP2010/006114 WO2011042180A1 (en) 2009-10-08 2010-10-06 Generation of a broad t-cell response in humans against hiv

Publications (2)

Publication Number Publication Date
JP2013507107A JP2013507107A (ja) 2013-03-04
JP2013507107A5 true JP2013507107A5 (https=) 2013-11-07

Family

ID=46396898

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012532489A Withdrawn JP2013507107A (ja) 2009-10-08 2010-10-06 Hivに対するヒトにおける広範なt細胞応答の生成

Country Status (11)

Country Link
US (1) US20120135032A1 (https=)
EP (1) EP2486138A1 (https=)
JP (1) JP2013507107A (https=)
KR (1) KR20120093941A (https=)
CN (1) CN102656271A (https=)
AU (1) AU2010305030A1 (https=)
CA (1) CA2767924A1 (https=)
EA (1) EA201270108A1 (https=)
MX (1) MX2012002531A (https=)
SG (1) SG178909A1 (https=)
WO (1) WO2011042180A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2620446A1 (en) * 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
KR102269491B1 (ko) * 2013-03-15 2021-06-25 버베리안 노딕 에이/에스 단회 고용량의 mva가 신생아 및 영아에서 보호 면역 반응을 유도
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
EP3319631A4 (en) 2015-07-08 2019-01-09 American Gene Technologies International Inc. HIV PREMUNICATION AND IMMUNOTHERAPY
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
WO2017139065A1 (en) 2016-02-08 2017-08-17 American Gene Technologies International Inc. Hiv vaccination and immunotherapy
AU2017292582C1 (en) 2016-07-08 2021-11-11 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
TWI810456B (zh) 2019-05-22 2023-08-01 美商基利科學股份有限公司 Tlr7調節化合物及hiv疫苗之組合
US12514921B2 (en) 2019-06-27 2026-01-06 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for treating HIV infection and reversing HIV latency
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787901A (fr) 1971-09-11 1972-12-18 Freistaat Bayern Represente Pa Vaccin antivariolique
AU784679B2 (en) 1999-12-23 2006-05-25 International Aids Vaccine Initiative Improvements in or relating to immune responses to HIV
KR100815888B1 (ko) * 2000-07-14 2008-03-21 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Hiv 보조 단백질을 암호화하는 dna 백신
UA76731C2 (uk) 2000-11-23 2006-09-15 Баваріан Нордік А/С Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
CA2467365C (en) 2001-12-10 2012-11-20 Bavarian Nordic A/S Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions
UA82998C2 (ru) * 2002-05-16 2008-06-10 Бавариан Нордик А/С Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті
US7501127B2 (en) * 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
WO2003097844A1 (en) 2002-05-16 2003-11-27 Bavarian Nordic A/S Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
ATE315660T1 (de) 2002-05-16 2006-02-15 Bavarian Nordic As Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva)
EP1856143A2 (en) 2005-02-24 2007-11-21 Medical Research Council Hivcon: anhiv immunogen and uses thereof
ES2281252B1 (es) 2005-07-27 2009-02-16 Consejo Superior De Investigaciones Cientificas Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.
AU2008230849A1 (en) 2007-03-26 2008-10-02 International Aids Vaccine Initiative Method of eliciting immune response with a modified MVA viral HIV-1 vector
US8268327B2 (en) * 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
WO2009056535A2 (en) * 2007-10-29 2009-05-07 Genimmune N.V. Methods and kits for inducing a ctl response using a prime boost regimen

Similar Documents

Publication Publication Date Title
JP2013507107A5 (https=)
AU2018267669B2 (en) Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
JP2012509340A5 (https=)
ES2396376T3 (es) Sitios intergénicos entre genes conservados en el genoma del virus vaccinia Ankara modificado (MVA)
Hanke Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines
US9133480B2 (en) Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites
CN105051198A (zh) 重组腺病毒及其用途
EA201270108A1 (ru) Формирование полиспецифического t-клеточного ответа против вич у человека
JP6177981B2 (ja) 迅速かつ持続的な免疫学的治療法
ES2399875T3 (es) Composiciones de vacunas de ADN y procedimientos para su uso
WO2013026452A1 (en) Method for removing immunosuppresive properties of hiv envelope glycoproteins
WO2007137591A8 (en) Hiv vaccine
CN103298936A (zh) 具有新型流感病毒来源的血凝素蛋白基因的重组痘苗病毒
Chen et al. Design, construction, and characterization of a multigenic modified vaccinia Ankara candidate vaccine against human immunodeficiency virus type 1 subtype C/B′
Xu et al. Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques
US20240093234A1 (en) Chimeric adenoviral vectors
Biberfeld et al. Protection against human immunodeficiency virus type 2 and simian immunodeficiency virus in macaques vaccinated against human immunodeficiency virus type 2
WO2013010300A1 (zh) 四种及四种以上载体的hiv组合疫苗及应用
Seth et al. Development of Indian HIV-1 Subtype C Vaccine Candidates
Nelson et al. The influence of Influenza: is the Influenza vaccine as useful as we thought?
Peng CONSTRUCTION AND CHARACTERIZATION OF REPLICATION
McKenna Characterization and immunogenicity of recombinant rhabdoviral vaccine vectors expressing HIV-1 and SIV envelope proteins
OA18541A (en) Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
NZ767061B2 (en) Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
NZ767061A (en) Methods and compositions for inducing protective immunity against human immunodeficiency virus infection